Treatment of HSV Lung Infection (Pneumonia)
For confirmed HSV pneumonia in critically ill or immunocompromised patients, initiate intravenous acyclovir at 5–10 mg/kg every 8 hours, adjusted for renal function, and continue until clinical improvement is documented. 1, 2
Diagnostic Confirmation Required Before Treatment
True HSV pneumonia is rare and must be distinguished from simple viral shedding or colonization. 3, 4 Treatment should be reserved for patients with:
- Clinical pneumonia symptoms (fever, respiratory distress, infiltrates on imaging) 5
- HSV detected in bronchoalveolar lavage (BAL) fluid with either:
- Cytopathic changes on cytology, OR
- Viral load >10⁵ copies/million cells 5
- Absence of alternative explanation for respiratory deterioration 4
The presence of HSV in upper respiratory tract samples alone does not indicate pneumonia and should not trigger treatment. 3, 5
Recommended Treatment Regimen
Standard Dosing (Normal Renal Function)
- Adults and immunocompromised patients: Acyclovir 5–10 mg/kg IV every 8 hours 1, 2
- Severe or disseminated HSV infection: Use the higher end of dosing (10 mg/kg IV every 8 hours) 1, 2
- Duration: Continue until clinical improvement, typically 14–21 days for severe visceral involvement 1, 2
Renal Dose Adjustments
Acyclovir is 62–91% renally excreted and must be dose-adjusted in renal impairment. 6, 7
| Creatinine Clearance | Recommended IV Dose |
|---|---|
| >50 mL/min | 5–10 mg/kg every 8 hours |
| 25–50 mL/min | 5–10 mg/kg every 12 hours |
| 10–24 mL/min | 5–10 mg/kg every 24 hours |
| <10 mL/min | 2.5–5 mg/kg every 24 hours |
| Hemodialysis | 2.5–5 mg/kg every 24 hours; dose after dialysis |
Critical Management Considerations
Hydration and Nephrotoxicity Prevention
- Maintain aggressive hydration throughout treatment to prevent acyclovir crystalluria and obstructive nephropathy 6, 7
- Monitor renal function (serum creatinine, urine output) regularly, as nephrotoxicity occurs in up to 20% of patients after approximately 4 days of IV therapy 6, 8
- Infuse slowly over 1 hour rather than as rapid bolus to reduce crystal precipitation 6
Immunosuppression Reduction
- Consider reducing immunosuppressive medications in transplant recipients or other immunocompromised patients with severe HSV pneumonia until infection resolves 1, 2
- This applies particularly to life-threatening disease that persists despite antiviral therapy 1
Oral Therapy is Contraindicated
- Never use oral acyclovir, valacyclovir, or famciclovir for acute HSV pneumonia, as these do not achieve adequate tissue concentrations in severe visceral infections 6, 8, 2
- Oral agents are appropriate only for superficial mucocutaneous HSV infections 1
Acyclovir-Resistant HSV
Resistance is uncommon in solid organ transplant recipients but should be suspected when:
- Clinical deterioration persists after 7–10 days of appropriate acyclovir therapy 2
- Lesions or viral shedding continue despite treatment 1, 2
Second-line therapy: Foscarnet 40 mg/kg IV every 8 hours (or 60 mg/kg IV every 12 hours) for 2–3 weeks or until clinical improvement 1, 8, 2
Evidence Limitations and Clinical Judgment
The evidence base for HSV pneumonia treatment is limited because:
- No randomized trials have demonstrated benefit of prophylactic or preemptive acyclovir in mechanically ventilated patients 5
- Observational data suggest potential benefit when acyclovir is used as curative treatment in confirmed HSV bronchopneumonitis 5
- HSV reactivation is common (20–50%) in ICU patients, but true pneumonia is rare 5
Therefore, treatment should be reserved for patients meeting strict diagnostic criteria (clinical pneumonia + high viral load or cytopathic changes in BAL), rather than treating all HSV-positive respiratory samples. 5